In a statement, Moderna said it had completed manufacturing doses of a new version of its Covid-19 vaccine modified to target the South Africa strain, or B.1.351, and shipped it to researchers at the National Institutes of Health for clinical study. The South Africa booster shot is part of a multi-pronged strategy Moderna is taking against new variants, the company said.
In addition to the South Africa ...
Learn more about Bloomberg Law or Log In to keep reading:
Learn About Bloomberg Law
AI-powered legal analytics, workflow tools and premium legal & business news.
Already a subscriber?
Log in to keep reading or access research tools.